Cargando…

Cardiac toxic effect of radiation therapy in patients receiving adjuvant trastuzumab treatment, as examined by LVEF of echocardiography: an experimental research

Radiation in breast cancer patients may result in cardiovascular disease affecting the pericardium, myocardium, and cardiac valves. OBJECTIVE: This study aimed to evaluate the cardiotoxic consequences of radiotherapy in breast cancer patients who underwent adjuvant trastuzumab treatment by echocardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khandoozi, Reza, Gelvardi, Mohsen S., Khoshbin Khoshnazar, Alireza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328589/ https://www.ncbi.nlm.nih.gov/pubmed/37427221 http://dx.doi.org/10.1097/MS9.0000000000000529

Ejemplares similares

Comparison Of Accelerated Partial Breast Radiation Therapy And External Beam Radiation Therapy By Treatment Planning Indices
por: Hejazi, Peyman, et al.
Publicado: (2019)

Assessment of LVEF using a new 16-segment wall motion score in echocardiography
por: Lebeau, Real, et al.
Publicado: (2018)

Effects of Different LVEF Assessed by Echocardiography and CMR on the Diagnosis and Therapeutic Decisions of Cardiovascular Diseases
por: Zhao, Lei, et al.
Publicado: (2020)

Changes in the Radiation Toxicity of Human Lymphoblastic T-cell Line (Jurkat) by a Common Pesticide: Diazinon
por: Sh., Ghasemi, et al.
Publicado: (2020)

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2019)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

A machine learning algorithm supports ultrasound-naïve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF
por: Schneider, Matthias, et al.
Publicado: (2020)

Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy
por: Parrington, Diane J, et al.
Publicado: (2012)

Chronic Heart Failure: Diagnosis and Management beyond LVEF Classification
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF
por: Triposkiadis, Filippos, et al.
Publicado: (2023)

Clinical Relevance of the LVEDD and LVESD Trajectories in HF Patients With LVEF < 35%
por: Chen, Yu-Chen, et al.
Publicado: (2022)

Investigation on left ventricular multi-directional deformation in patients of hypertension with different LVEF
por: Huang, Huimei, et al.
Publicado: (2017)

Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors
por: Reding, Kerryn W., et al.
Publicado: (2021)

Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy
por: Jolly, Marie-Pierre, et al.
Publicado: (2017)

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Effectiveness of adjuvant trastuzumab in daily clinical practice
por: Matos, Erika, et al.
Publicado: (2014)

Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab
por: Cao, Lu, et al.
Publicado: (2015)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab
por: Dobson, Rebecca, et al.
Publicado: (2021)

Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab
por: Shinano, Hiromi, et al.
Publicado: (2020)

CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin
por: Lang, Jennifer K., et al.
Publicado: (2021)

LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review
por: Printezi, Markella I., et al.
Publicado: (2022)

Machine learning-aided detection of heart failure (LVEF ≤ 49%) by using ballistocardiography and respiratory effort signals
por: Feng, Shen, et al.
Publicado: (2023)

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
por: Athanasakis, Kostas, et al.
Publicado: (2016)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!
por: Verma, Sunil
Publicado: (2008)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
por: Kim, In-Ho, et al.
Publicado: (2017)

Echocardiographic indices of left ventricular hypertrophy and diastolic function in hypertensive patients with preserved LVEF classified as dippers and non-dippers
por: Możdżan, Monika, et al.
Publicado: (2013)

Prevalence of QT prolongation and associated LVEF changes in diabetic patients over a four-year retrospective time period
por: Lu, Zhongju, et al.
Publicado: (2017)

Predictive values of heart rate variability, deceleration and acceleration capacity of heart rate in post‐infarction patients with LVEF ≥35%
por: Liu, Xiang, et al.
Publicado: (2020)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
por: Davari, Majid, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
por: Shrivastva, Sarita, et al.
Publicado: (2023)

Cardiac toxicity of trastuzumab in elderly patients with breast cancer
por: Denegri, Andrea, et al.
Publicado: (2016)

Levosimendan benefits critically ill patients with decompensated heart failure assessed with plasma B-type natriuretic peptide (BNP) and LVEF
por: McLean, AS, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_mtfgdu477dr9fdb83mq6pbkars